<!DOCTYPE html><html><head><title> Pacifica Code Section 26-18-S107 </title><link rel="stylesheet" href="../../../assets/style.css"/></head><body>
<b><i>
                      Effective 5/14/2019</i></b>
<br>
<b>26-18-107.&nbsp;
          </b><b>Retrospective and prospective DUR.</b>
<br>
<a id="26-18-107(1)" name="26-18-107(1)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(1)</td><td style="width:99%">
The board, in cooperation with the division, shall include in its state plan the creation and implementation of a retrospective and prospective DUR program for Medicaid outpatient drugs to ensure that prescriptions are appropriate, medically necessary, and not likely to result in adverse medical outcomes.</td>
</tr>
</tbody></table>
<a id="26-18-107(2)" name="26-18-107(2)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(2)</td><td style="width:99%">
The retrospective and prospective DUR program shall be operated under guidelines established by the board under Subsections <a href="#26-18-107(3)">(3)</a> and <a href="#26-18-107(4)">(4)</a>.</td>
</tr>
</tbody></table>
<a id="26-18-107(3)" name="26-18-107(3)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(3)</td><td style="width:99%">
The retrospective DUR program shall be based on guidelines established by the board, using the mechanized drug claims processing and information retrieval system to analyze claims data in order to:
<a id="26-18-107(3)(a)" name="26-18-107(3)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
identify patterns of fraud, abuse, gross overuse, and inappropriate or medically unnecessary care; and</td>
</tr>
</tbody></table>
<a id="26-18-107(3)(b)" name="26-18-107(3)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
assess data on drug use against explicit predetermined standards that are based on the compendia and other sources for the purpose of monitoring:<a id="26-18-107(3)(b)(i)" name="26-18-107(3)(b)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
therapeutic appropriateness;</td>
</tr>
</tbody></table>
<a id="26-18-107(3)(b)(ii)" name="26-18-107(3)(b)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
overutilization or underutilization;</td>
</tr>
</tbody></table>
<a id="26-18-107(3)(b)(iii)" name="26-18-107(3)(b)(iii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(iii)</td><td style="width:99%">
therapeutic duplication;</td>
</tr>
</tbody></table>
<a id="26-18-107(3)(b)(iv)" name="26-18-107(3)(b)(iv)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(iv)</td><td style="width:99%">
drug-disease contraindications;</td>
</tr>
</tbody></table>
<a id="26-18-107(3)(b)(v)" name="26-18-107(3)(b)(v)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(v)</td><td style="width:99%">
drug-drug interactions;</td>
</tr>
</tbody></table>
<a id="26-18-107(3)(b)(vi)" name="26-18-107(3)(b)(vi)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(vi)</td><td style="width:99%">
incorrect drug dosage or duration of drug treatment; and</td>
</tr>
</tbody></table>
<a id="26-18-107(3)(b)(vii)" name="26-18-107(3)(b)(vii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(vii)</td><td style="width:99%">
clinical abuse and misuse.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-107(4)" name="26-18-107(4)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(4)</td><td style="width:99%">
The prospective DUR program shall be based on guidelines established by the board and shall provide that, before a prescription is filled or delivered, a review will be conducted by the pharmacist at the point of sale to screen for potential drug therapy problems resulting from:
<a id="26-18-107(4)(a)" name="26-18-107(4)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
therapeutic duplication;</td>
</tr>
</tbody></table>
<a id="26-18-107(4)(b)" name="26-18-107(4)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
drug-drug interactions;</td>
</tr>
</tbody></table>
<a id="26-18-107(4)(c)" name="26-18-107(4)(c)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(c)</td><td style="width:99%">
incorrect dosage or duration of treatment;</td>
</tr>
</tbody></table>
<a id="26-18-107(4)(d)" name="26-18-107(4)(d)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(d)</td><td style="width:99%">
drug-allergy interactions; and</td>
</tr>
</tbody></table>
<a id="26-18-107(4)(e)" name="26-18-107(4)(e)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(e)</td><td style="width:99%">
clinical abuse or misuse.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-107(5)" name="26-18-107(5)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(5)</td><td style="width:99%">
In conducting the prospective DUR, a pharmacist may not alter the prescribed outpatient drug therapy without the consent of the prescribing physician or physician assistant.  This section does not effect the ability of a pharmacist to substitute a generic equivalent.</td>
</tr>
</tbody></table>
<br>
<br>Amended by Chapter <a href="http://le.utah.gov/UtahCode/ChapterLookup.jsp?chap=349&amp;sess=2019GS">349</a>, 2019 General Session<br>
</body></html>